Biogen update on European access to Spinraza
Here is an update on reimbursed access to Spinraza treatment in the Europe and Middle East region.
UK campaign for access to treatments and support for those with spinal muscular atrophy
BLOG ARCHIVE
Biogen update on European access to Spinraza
Here is an update on reimbursed access to Spinraza treatment in the Europe and Middle East region.
Risdiplam update from Roche
On 5th July Roche sent us the following information, as per our request to be kept up to date on their current research regarding the RG7916 development programme which will now be known as “risdiplam”. The programme has now reached a number of key milestones. They also announced a new study called RAINBOWFISH which will…
Risdiplam update from Roche
On 5th July Roche sent us the following information, as per our request to be kept up to date on their current research regarding the RG7916 development programme which will now be known as “risdiplam”. The programme has now reached a number of key milestones. They also announced a new study called RAINBOWFISH which will…
Spinraza appraisal at NICE
TreatSMA attended an important meeting on Spinraza appraisal at NICE offices in Manchester on 27 June.
Spinraza appraisal at NICE
TreatSMA attended an important meeting on Spinraza appraisal at NICE offices in Manchester on 27 June.
Exciting news about new oral molecule for SMA
Risdiplam – a new name for RG7916 – is showing fantastic results in babies participating in the Firefish clinical trial. Almost all the participating babies are progressing well and gaining motor function.
Exciting news about new oral molecule for SMA
Risdiplam – a new name for RG7916 – is showing fantastic results in babies participating in the Firefish clinical trial. Almost all the participating babies are progressing well and gaining motor function.
Scotland: new approval pathway for ultra-orphan medicines
People in Scotland with rare diseases may be able to access new treatments in a more efficient manner following the introduction of a new definition of ‘ultra-orphan medicines’.